Milestone Pharmaceuticals Patent Term Extension Application

Clark & Elbing, LLP submitted a patent term extension application to FDA on behalf of Milestone Pharmaceuticals, Inc. The application, filed under 35 U.S.C. 156, seeks to restore or extend patent term for a pharmaceutical product lost during FDA regulatory review and approval process.

Pharmaceutical companies facing similar patent expiration concerns near product approvals may want to monitor FDA's review of this application. Patent term extensions can add up to 5 years to the effective patent life, providing additional market exclusivity. Generic and biosimilar manufacturers should track pending extensions as they affect competitive timelines.